ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Nonobstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

enavogliflozin 0.3mg

"Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."

DRUG

enavogliflozin Placebo

"A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."

Trial Locations (1)

03722

RECRUITING

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06580717 - ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy | Biotech Hunter | Biotech Hunter